Efficacy and safety of remimazolam besylate versus propofol during hysteroscopy: single-centre randomized controlled trial
Abstract Background Remimazolam besylate is a newer benzodiazepine with characteristics of quick onset of effects, short maintenance and recovery times without accumulation in tissues. This trial was conducted to confirm the efficacy and safety of remimazolam besylate versus propofol during hysteros...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-05-01
|
Series: | BMC Anesthesiology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12871-021-01373-y |
id |
doaj-a3fe76146e8b4af29347e0e4bc822223 |
---|---|
record_format |
Article |
spelling |
doaj-a3fe76146e8b4af29347e0e4bc8222232021-05-23T11:30:19ZengBMCBMC Anesthesiology1471-22532021-05-012111810.1186/s12871-021-01373-yEfficacy and safety of remimazolam besylate versus propofol during hysteroscopy: single-centre randomized controlled trialXiaoqiang Zhang0Shuang Li1Jing Liu2Department of Anaesthesiology, Mengcheng County No. 1 People’s HospitalDepartment of Anaesthesiology, Mengcheng County No. 1 People’s HospitalDepartment of Anaesthesiology, Mengcheng County No. 1 People’s HospitalAbstract Background Remimazolam besylate is a newer benzodiazepine with characteristics of quick onset of effects, short maintenance and recovery times without accumulation in tissues. This trial was conducted to confirm the efficacy and safety of remimazolam besylate versus propofol during hysteroscopy. Methods Patients undergoing hysteroscopy were randomly assigned to either the remimazolam (Group R) or the propofol group (Group P). Group R was administered an induction dose of 0.2 mg/kg and a maintenance dosage of 1.0 mg/kg/h. In Group P, propofol was started at 1.5–2.0 mg/kg and then maintained at 3.0–6.0 mg/kg/h. After remimazolam besylate or propofol induction, remifentanil was infused using a target-controlled infusion system with a target concentration of 1.5 ng/ml and titrated during the procedure. The incidence rates of injection pain, low oxygen saturation (SpO2) and adverse effects in both groups were compared. Results Eighty-two patients were included in this study. The incidence of adverse events in Group R (3.7%) was significantly lower than that in Group P (36.6%) (p < 0.001). The incidence of injection pain in Group P (80.5%) was much higher than that in Group R (2.4%) (p < 0.001). The incidence of other adverse events, such as low SpO2, bradycardia, and hypotension in Group R was lower than that in Group P (p < 0.05). Conclusions Remimazolam besylate proves to be a safer alternative for anesthesia during hysteroscopy. Moreover, adverse events caused by propofol, such as low SpO2 and injection pain, are largely avoided. Trial registration This study was approved by the Clinical Research Ethics Committee of Mengcheng County No. 1 People’s Hospital (2020MYL20003) and registered at http://www.chictr.org.cn (15/09/2020, ChiCTR-2000038252 ). The study protocol followed the CONSORT guidelines. The study protocol was performed in the relevant guidelines.https://doi.org/10.1186/s12871-021-01373-yAnaesthesiaRemimazolam besylateBenzodiazepinePropofolRemifentanilHysteroscopy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Xiaoqiang Zhang Shuang Li Jing Liu |
spellingShingle |
Xiaoqiang Zhang Shuang Li Jing Liu Efficacy and safety of remimazolam besylate versus propofol during hysteroscopy: single-centre randomized controlled trial BMC Anesthesiology Anaesthesia Remimazolam besylate Benzodiazepine Propofol Remifentanil Hysteroscopy |
author_facet |
Xiaoqiang Zhang Shuang Li Jing Liu |
author_sort |
Xiaoqiang Zhang |
title |
Efficacy and safety of remimazolam besylate versus propofol during hysteroscopy: single-centre randomized controlled trial |
title_short |
Efficacy and safety of remimazolam besylate versus propofol during hysteroscopy: single-centre randomized controlled trial |
title_full |
Efficacy and safety of remimazolam besylate versus propofol during hysteroscopy: single-centre randomized controlled trial |
title_fullStr |
Efficacy and safety of remimazolam besylate versus propofol during hysteroscopy: single-centre randomized controlled trial |
title_full_unstemmed |
Efficacy and safety of remimazolam besylate versus propofol during hysteroscopy: single-centre randomized controlled trial |
title_sort |
efficacy and safety of remimazolam besylate versus propofol during hysteroscopy: single-centre randomized controlled trial |
publisher |
BMC |
series |
BMC Anesthesiology |
issn |
1471-2253 |
publishDate |
2021-05-01 |
description |
Abstract Background Remimazolam besylate is a newer benzodiazepine with characteristics of quick onset of effects, short maintenance and recovery times without accumulation in tissues. This trial was conducted to confirm the efficacy and safety of remimazolam besylate versus propofol during hysteroscopy. Methods Patients undergoing hysteroscopy were randomly assigned to either the remimazolam (Group R) or the propofol group (Group P). Group R was administered an induction dose of 0.2 mg/kg and a maintenance dosage of 1.0 mg/kg/h. In Group P, propofol was started at 1.5–2.0 mg/kg and then maintained at 3.0–6.0 mg/kg/h. After remimazolam besylate or propofol induction, remifentanil was infused using a target-controlled infusion system with a target concentration of 1.5 ng/ml and titrated during the procedure. The incidence rates of injection pain, low oxygen saturation (SpO2) and adverse effects in both groups were compared. Results Eighty-two patients were included in this study. The incidence of adverse events in Group R (3.7%) was significantly lower than that in Group P (36.6%) (p < 0.001). The incidence of injection pain in Group P (80.5%) was much higher than that in Group R (2.4%) (p < 0.001). The incidence of other adverse events, such as low SpO2, bradycardia, and hypotension in Group R was lower than that in Group P (p < 0.05). Conclusions Remimazolam besylate proves to be a safer alternative for anesthesia during hysteroscopy. Moreover, adverse events caused by propofol, such as low SpO2 and injection pain, are largely avoided. Trial registration This study was approved by the Clinical Research Ethics Committee of Mengcheng County No. 1 People’s Hospital (2020MYL20003) and registered at http://www.chictr.org.cn (15/09/2020, ChiCTR-2000038252 ). The study protocol followed the CONSORT guidelines. The study protocol was performed in the relevant guidelines. |
topic |
Anaesthesia Remimazolam besylate Benzodiazepine Propofol Remifentanil Hysteroscopy |
url |
https://doi.org/10.1186/s12871-021-01373-y |
work_keys_str_mv |
AT xiaoqiangzhang efficacyandsafetyofremimazolambesylateversuspropofolduringhysteroscopysinglecentrerandomizedcontrolledtrial AT shuangli efficacyandsafetyofremimazolambesylateversuspropofolduringhysteroscopysinglecentrerandomizedcontrolledtrial AT jingliu efficacyandsafetyofremimazolambesylateversuspropofolduringhysteroscopysinglecentrerandomizedcontrolledtrial |
_version_ |
1721429719316955136 |